Ionis reports second quarter 2020 financial results and recent business achievements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 4c
August 5, 2020 7:15 AM EDTIonis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $146 million versus the consensus estimate of $148.87 million.
Second Quarter 2020 Financial Results and Highlights
On track to achieve financial guidance of being meaningfully profitable this yearNet income of $8 million on a non-GAAP basis and a net loss of $32 million on a GAAP basisAchieved quarter over quarter growth in commercial and R&D revenuesCommercial revenue from SPINRAZA® (nusinersen) royalties increased to $72... More